Hes6 is required for MyoD induction during gastrulation  by Murai, Kasumi et al.
Available online at www.sciencedirect.com
312 (2007) 61–76
www.elsevier.com/developmentalbiologyDevelopmental BiologyHes6 is required for MyoD induction during gastrulation
Kasumi Murai a, Ann E. Vernon b,c, Anna Philpott b, Phil Jones a,⁎
a MRC Cancer Cell Unit, Hutchison–MRC Research Centre, Addenbrooke’s Hospital, Cambridge CB2 0XZ, UK
b Department of Oncology, University of Cambridge, Hutchison–MRC Research Centre, Addenbrooke’s Hospital, Cambridge CB2 0XZ, UK
c Abramson Family Cancer Research Institute, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, PA, 19104-6160, USA
Received for publication 12 March 2007; revised 22 August 2007; accepted 5 September 2007
Available online 16 September 2007Abstract
The specification of mesoderm into distinct compartments sharing the same lineage restricted fates is a crucial step occurring during
gastrulation, and is regulated by morphogenic signals such as the FGF/MAPK and activin pathways. One target of these pathways is the
transcription factor XmyoD, which in early gastrulation is expressed in the lateral and ventral mesoderm. Expression of the hairy/enhancer of split
transcription factor hes6, is also restricted to lateral and ventral mesoderm in gastrula stage Xenopus embryos, leading us to investigate whether it
has a role in XmyoD regulation. In vivo, Xhes6 is required for FGF-mediated induction of XmyoD expression but not for induction of early
mesoderm. The WRPW domain of Xhes6, which binds Groucho family transcriptional co-regulators, is essential for the XmyoD-inducing activity
of Xhes6. Two Groucho proteins, Xgrg2 and Xgrg4, are expressed in lateral and ventral mesoderm, and inhibit expression of XmyoD. Xhes6 binds
both Xgrg2 and Xgrg4 and relieves their inhibition of XmyoD expression. We also find that lowering Xhes6 expression levels blocks normal
myogenic differentiation at tail bud stage. We conclude that Xhes6 is essential for XmyoD induction and acts by relieving Groucho-mediated
repression of gene expression.
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The specification of mesoderm into spatially defined
compartments that will develop into different tissues is a crucial
process occurring in early gastrulation. An early marker of
mesodermal specification is the transcription factor XmyoD,
which in early to mid gastrula embryos identifies the lateral
mesoderm that will give rise to the somites and ventral marginal
zone mesoderm which later forms the lateral plate mesoderm,
mesenchyme and blood (Frank and Harland, 1991; Hopwood
and Gurdon, 1990; Hopwood et al., 1991; Scales et al., 1990).
The expression of XmyoD is regulated by mesoderm-inducing/
patterning signals such as members of FGF, TGFβ/activin and
Wnt protein families. A key challenge in understanding
mesodermal specification is to determine how such signals are⁎ Corresponding author. Fax: +44 1223 763296.
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doi:10.1016/j.ydbio.2007.09.011integrated to generate distinct mesodermal domains such as the
future myotome.
Three mesodermal-inducing factors, FGF, activin and Xwnt8
have been shown to regulate expression of XmyoD (Cornell and
Kimelman, 1994; Fisher et al., 2002; Hoppler et al., 1996). As
gastrulation proceeds, FGF/MAP kinase (MAPK) signaling is
further required for dorsal/ventral patterning of mesodermal fate
within the domain of XmyoD expression, inhibiting lateral
mesoderm from adopting blood island fate (Isaacs et al., 2007;
Kumano et al., 2001; Kumano and Smith, 2000). FGF3, FGF 8
and FGF4 (also known as eFGF) are all expressed in the
mesoderm of early gastrula embryo (Fisher et al., 2002; Isaacs
et al., 1995; Lombardo et al., 1998). There is strong evidence for
eFGF in particular being essential for regulating expression of
XmyoD, as blocking translation of eFGF protein or inhibiting
FGF signaling with the pharmacological inhibitor SU5402
results in a dramatic downregulation of XmyoD transcription
(Fisher et al., 2002; Isaacs et al., 2007). Unique among
mesodermal-inducing factors, eFGF is responsible for the
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clusters of early muscle precursors. Without eFGF signaling
from adjacent precursor cells, terminal muscle differentiation is
blocked (Standley et al., 2001). Furthermore, phosphorylated
ERK, a target of FGF signaling, is detectable in the region of
XmyoD expression (Christen and Slack, 1999). More recently,
it has been shown that FGF8 is required for normal induction of
XmyoD at gastrulation in Xenopus and also controls myoD
expression in somite stage Zebrafish embryos (Fletcher et al.,
2006; Groves et al., 2005; Hamade et al., 2006). These
observations provide convincing evidence for regulation of
XmyoD expression by FGF. Activin can induce both the pan-
mesodermal marker Xbra and XmyoD but it requires an intact
FGF signaling pathway to do so (Cornell and Kimelman, 1994;
LaBonne and Whitman, 1994). Likewise, Xwnt8 is necessary
for XmyoD expression but in embryos in which FGF signaling
has been blocked, XmyoD is not induced, despite Xwnt8 levels
being normal (Hoppler et al., 1996; Isaacs et al., 1994).
The mesodermal compartments in the early gastrula embryo
have clearly defined boundaries, for example between the
lateral and ventral mesoderm and the notochord. However, little
is known about how diffusible morphogens are able to
demarcate mesodermal compartments. One possible explana-
tion is that the effects of morphogens are modulated by
regulatory factors whose expression is confined to specific
mesodermal compartments. Such factors may act to adjust the
level of mesoderm-inducing activity above or below the
threshold levels required to specify the appropriate subtype of
mesoderm (Green and Smith, 1990; Umbhauer et al., 1995).
Candidate regulators of XmyoD expression include Hairy/
Enhancer of split-related (hes) genes, which encode a family of
basic helix–loop–helix (bHLH) type transcriptional regulators.
Hes proteins share highly conserved domains, including a basic
region of the bHLH domain, containing a characteristic proline
residue and a C-terminal WRPW motif that binds to the
transcriptional repressor Groucho/TLE family of proteins
(Dawson et al., 1995; Grbavec and Stifani, 1996; Paroush et
al., 1994). Several members of the family, such as hes1, hes5
and hes7 are direct targets of the Notch signaling pathway,
whilst others such as hes6 are not regulated by Notch, but are
induced by FGF signaling (Kawamura et al., 2005; Koyano-
Nakagawa et al., 2000). Hes6 also differs from other hes
proteins in having a shorter loop within its DNA binding
domain. This feature is highly conserved between mammalian
Hes6 and its Xenopus homologue, Xhes6, that confers DNA
binding properties distinct from other Hes proteins (Bae et al.,
2000; Cossins et al., 2002; Koyano-Nakagawa et al., 2000).
Overexpression of Xhes6 in Xenopus embryos expands the
myotome but blocks myogenic terminal differentiation at the
tail bud stage (Cossins et al., 2002).
We have previously observed that both Xhes6 and XmyoD
share the same pattern of gene expression in early gastrula
stage Xenopus embryos (Cossins et al., 2002). This observa-
tion, combined with the strong body of evidence that XmyoD
is induced by FGF signaling in gastrulation, led us to speculate
that, as well as being induced by the morphogen FGF
(Kawamura et al., 2005), Xhes6 may have a novel role inregulating FGF-induced gene expression within the mesoder-
mal compartment. To test this hypothesis we first showed that
expression of both Xhes6 and XmyoD requires FGF signaling.
We then investigated the effect of Xhes6 function on
mesoderm specification, both in vitro, in the well-defined
ectodermal explant (animal cap) assay system and in vivo,
using Xhes6 morpholino oligonucleotides (MO) to knock
down expression of Xhes6 protein. We find that Xhes6 acts by
relieving Groucho-mediated inhibition of XmyoD expression,
permitting induction of XmyoD by FGF/MAP kinase signaling.
This function is mediated by the ability of Xhes6 to bind
Groucho family transcriptional repressor proteins Xgrg2 and
Xgrg4.
Results
Xhes6 expression in the lateral and ventral mesoderm is
regulated by FGF and nodal signaling
As reported previously, Xhes6 is co-expressed with XmyoD
in the lateral and ventral mesoderm of early gastrula stage
embryos (Figs. 1A, B; Cossins et al., 2002). This led us to
investigate if Xhes6 expression was regulated by the same
signaling pathways that regulate XmyoD transcription. Over-
expression of mRNAs encoding either the TGFβ/Nodal family
member, Xnr2, or eFGF resulted in an increased expression not
only of XmyoD, as reported previously, but also of Xhes6 (Figs.
1C–F) (Fisher et al., 2002; Isaacs et al., 2007; Kofron et al.,
1999). Furthermore, inhibition of FGF signaling by over-
expression of the dominant negative FGF receptor, XFD,
abolished the expression of both XmyoD and Xhes6 (Figs. 1G,
H) (Amaya et al., 1991; Isaacs et al., 1994). Thus, Xhes6 is a
target of both nodal and FGF signaling, and requires FGF
signaling for its expression, consistent with previous reports that
a hes6-related gene is an FGF target in Zebrafish (Kawamura et
al., 2005).
Xhes6 increases expression of XmyoD in vivo
The observation that Xhes6 transcription is both colocalised
with XmyoD expression and is regulated by the same
mesodermal patterning signals led us to investigate whether
Xhes6 plays a role in regulating XmyoD expression. Untagged
and N-terminally myc-tagged Xhes6 proteins were found to
have equivalent effects on XmyoD expression (data not shown).
Myc-tagged forms of Xhes6 were used in the experiments
reported here. We began by injecting embryos with mRNA
encoding wild-type and mutant forms of Xhes6 and assaying the
expression of XmyoD together with the mid mesodermal marker
Xbra, the ventro-lateral mesodermal marker Xwnt8 and the
dorsal lip mesoderm marker Chordin at early gastrula stage. We
found that overexpression of Xhes6 results in modest induction
of XmyoD (Fig. 2D) and smaller increases in Xbra and Xwnt8
expression (Figs. 2H, J), but had no effect on the chordin
expression (Fig. 2L). The zone of ectopic XmyoD expression
remains confined to mesoderm, suggesting that Xhes6 requires
additional factors whose expression is restricted to the
Fig. 1. Xhes6 is induced by mesoderm inducing signals and its expression is dependent on FGF-signaling. 5 pg of Xnr2 (C, D), 1 pg of eFGF (E, F) or 125 pg of XFD
(G, H) mRNAwas injected into a blastomere at 2-cell stage, along with β-galactosidase mRNA (red staining) and analyzed at gastrula stage for expression of Xhes6
(A, C, E and G) and XmyoD (B, D, F and H) by whole-mount in situ hybridisation. The side view of the area within the yellow box is shown on the right of each panel.
63K. Murai et al. / Developmental Biology 312 (2007) 61–76mesoderm to upregulate XmyoD expression rather than being
able to induce mesoderm directly.
Next we investigated which domains of Xhes6 were
required for its activity using the mutants shown in Fig. 2A
(Cossins et al., 2002; Koyano-Nakagawa et al., 2000).
Expression of each of the myc-tagged constructs was readily
detectable when the corresponding mRNAs were injected into
whole embryos, though ΔWRPW had a higher level of
expression than either Xhes6 or DBM, consistent with previous
reports (Fig. 2B) (Kang et al., 2005). The DNA binding mutant
(DBM) of Xhes6 in which the basic amino acids have been
mutated to acidic residues was found to have activity
equivalent to wild-type Xhes6, indicating that direct DNA-
binding is not absolutely required for mesoderm induction (Fig.
2E; Table 1). In contrast, a mutant in which the C-terminal
WRPW motif had been deleted (ΔWRPW) had substantially
reduced activity (Fig. 2F; Table 1), indicating that Xhes6
requires the Groucho-binding WRPW domain for significant
regulation of XmyoD expression.Xhes6 induces mesodermal gene expression in vitro
In parallel with the above in vivo studies, we investigated the
ability of Xhes6 to induce mesodermal gene expression in vitro,
using the well-characterized assay of mRNA microinjection
into Xenopus embryos followed by dissection of animal pole
explants (animal caps) at the blastula stage. When cultured in
the absence of mesoderm-inducing factors, animal caps adopt
an epidermal fate (Slack et al., 1987). When injected with
Xhes6 mRNA, we found that both Xbra and Xwnt8 were
induced (Supplementary Figs. 1A, B), but there was no increase
in expression of chordin (Supplementary Figs. 1C). Expression
of Mix1 and Mix2, markers of the mesoderm/endoderm
boundary was only minimally increased whilst the endoderm
markers such as Mixer and Sox17alpha were not induced
(Supplementary Figs. 1D, E and data not shown).
Strikingly, the pattern of genes induced by Xhes6 in animal
caps parallels that seen when caps are treated with FGF, which
induces Xwnt8, but not changes in gene expression following
Fig. 2. Over-expression of Xhes6 increases XmyoD expression in vivo. (A) Constructs used. Xhes6 constructs were myc tagged at the N-terminus. In the DBMmutant,
the basic amino acids in the DNA domain were mutated to acidic residues (underlined) whilst in the ΔWRPW mutant, the C-terminal WRPW protein–protein
interaction motif was replaced by a stop codon (red triangle). (B) Western blotting with an anti-myc antibody to detect Xhes6 protein (upper panel) and an anti-α-
tubulin antibody loading control (lower panel). (C–L) Effects of overexpression of wild-type and mutant Xhes6 500 pg of Xhes6, DBM or ΔWRPW mRNA was
injected into marginal zone of a blastomere at 2-cell stage, along with β-galactosidase mRNA (red staining) and analyzed at gastrula stage for expression of XmyoD
(C–F), Xbra (G, H), Xwnt8 (I, J) and Chordin (K, L) by whole-mount in situ hybridisation. The side view of the area within the yellow box is shown on the right of
each panel.
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Table 1
Effect of overexpression of wild-type or mutant Xhes6 on XmyoD expression at
gastrula stage




Exp. 1 2 3 4
Xhes6 15/18 (83) 11/15 (73) 14/16 (88) 8/10 (80) 81 59
DBM 6/12 (50) 13/16 (81) 9/16 (56) 8/9 (89) 69 53
ΔWRPW 1/8 (12.5) 2/16 (13) 2/15 (13) 0/9 (0) 9.8 48
Injected RNA
(pg)
125 125 250 125
Injected
stages
2-cell 4-cell 4-cell 8-cell
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(Supplementary Fig. 1).
Xhes6 enhances the effects of exogenous FGF
The above observations suggest that Xhes6 may cooperate
with FGF signaling to induce mesodermal genes in animal caps.
We therefore examined whether Xhes6 enhances the ability of
FGF to induce mesoderm and XmyoD in animal caps. In these
experiments, caps were treated with a low dose of FGF that
produced minimal but detectable induction of Xbra (Fig. 3A).
Both the wild-type and the DBM mutant of Xhes6 substantially
enhanced the induction of Xbra by FGF (Fig. 3A), whilst the
ΔWRPW mutant had a greatly decreased effect. A similar
enhancement of FGF effects on Xwnt8 and XmyoD expression
was seen (Figs. 3B, C), the activity of the ΔWRPWmutant was
again substantially lower, suggesting that most of the activity of
Xhes6 is WRPW domain-dependent. Thus, Xhes6 enhances the
ability of FGF to induce genes normally expressed in lateral and
ventral mesoderm in animal caps. This effect does not require
Xhes6 to bind toDNAbut does require an intactWRPWdomain.
Xhes6 cooperates with the MAPK pathway to induce
mesodermal gene expression
Several signal transduction pathways downstream of FGF
have been described (Carballada et al., 2001; Schlessinger,
2000). However, signaling via the Ras–Raf–MAPK pathway is
essential for the mesoderm-inducing activity of FGF in vitro
(LaBonne et al., 1995; Umbhauer et al., 1995). Furthermore,
expression of the MAPK target protein phospho-ERK is
confined to the mesoderm at gastrula stage, raising the
possibility that Xhes6 interacts with MAPK signaling in vivo
(Christen and Slack, 1999).
We therefore investigated whether Xhes6 could enhance
mesoderm induction brought about by the MAPK pathway
alone, using a constitutively active mutant of MEK1, i.e.
MEK1S→E (Cowley et al., 1994; Umbhauer et al., 1995). The
dose of MEK1S→E mRNA injected into embryos was titrated to
produce a low-level induction of both Xbra and XmyoD (Figs.
3D, E). This low dose of MEK1S→E was then co-injected into
embryos with Xhes6 mRNA (Figs. 3D, E). Animal caps co-
expressing Xhes6 and MEK1S→E exhibited a greater level ofXbra and XmyoD induction that are then produced by either
Xhes6 or MEK1S→E alone (Figs. 3D, E). We conclude that
Xhes6 enhances the ability of MAPK signaling to induce both
Xbra and XmyoD in vitro.
We went on to investigate the relationship between Xhes6
and MAPK signaling in vivo. mRNAs encoding MEK1S→E,
wild-type or mutant Xhes6 were injected singly or in
combination into the marginal zone of a cell in 2-cell stage
embryos (Fig. 3; Supplementary Table 1). Firstly, we analysed
the effect of injecting mRNA encoding the activated MAPK
mutant, MEK1S→E, alone, at the low dose which resulted in
increased XmyoD expression in about one-third of embryos.
This dose of MAPK not only induces XmyoD but also Xhes6
(Figs. 3F, G).
If Xhes6 regulates XmyoD expression, we reasoned that a
further increase in the level of Xhes6 expression beyond that
induced by MEK1S→E alone might further increase XmyoD
expression. To test this prediction, the effects of co-expression
of Xhes6 and MEK1S→E were examined. As expected,
injection of Xhes6 mRNA expanded the region of XmyoD
expression in gastrula embryos (Fig. 3H; Supplementary Table
1), whilst the ΔWRPW mutant had little effect on XmyoD
expression (Fig. 3J; Supplementary Table 1). However, the
extent of XmyoD expression was considerably expanded by co-
injection of Xhes6 and MEK1S→E mRNA (Fig. 3I; Supple-
mentary Table 1), beyond the extent seen with either Xhes6 or
MEK1S→E alone. In contrast co-injection of ΔWRPW produced
no enhancement of the effect seen with MEK1S→E alone (Fig.
3K; Supplementary Table 1).
Xhes6 is also able to enhance the ability of MEK1S→E to
induce Xbra in animal caps (Fig. 3D), so we investigated
whether a similar effect occurred in vivo. Whilst injection of
mRNA encoding Xhes6 or MEK1S→E alone had only a small
effect on Xbra induction in vivo (Fig. 2H and data not shown),
co-injection of Xhes6 and MEK1S→E mRNA resulted in a
significant increase in Xbra expression (data not shown),
consistent with the results of the corresponding animal cap
assays. This suggests that the reason why Xhes6 only had a
minor effect on Xbra induction in vivo is that the level of
endogenous MAPK activity limits Xbra expression (Fig. 2H).
Xhes6 requires FGF/MAPK signaling to induce mesodermal
genes
The above results led us to investigate whether Xhes6
overexpression requires FGF signaling to induce XmyoD in
whole embryos. Embryos were injected with mRNA encoding
the dominant negative FGF receptor, XFD, at 2-cell stage to
inhibit endogenous FGF signaling and assayed for Xbra and
XmyoD expression at early gastrula stage (Amaya et al.,
1991). Xhes6 overexpression was unable to rescue the loss of
either Xbra or XmyoD expression resulting from inhibition of
endogenous FGF signaling (Figs. 4A–D and data not shown),
indicating that Xhes6 requires endogenous FGF signaling to
induce mesodermal gene expression in vivo.
We also investigated further whether Xhes6 requires MAPK
activity to induce mesodermal gene expression in animal caps.
Fig. 3. Xhes6 enhances FGF/MAPK mediated mesoderm induction in animal caps. (A–E) Mesodermal marker gene induction. Animal caps were prepared from
embryos injected with mRNA encoding wild-type or mutant Xhes6 as in Fig. 2. Animal caps were cultured in the presence or absence of FGF and collected at stage 11
for real-time RT–PCR analysis. The expression of each mRNAwas normalised to level of ODC mRNA: (A) Xbra, (B) Xwnt8, (C) XmyoD. Data are from a typical
experiment performed in triplicate. (D, E) Xhes6 enhances mesoderm induction by an activated mutant of MEK1. Both blastomeres of 2-cell stage embryos were
injected with mRNAs encoding wild-type Xhes6, MEKS→E or a combination of both. Animal caps were dissected from uninjected or injected embryos at stage 9.
Real-time RT–PCR analysis of Xbra (D) and XmyoD (E) expression, normalised to ODC mRNA, in stage 11 animal caps from embryos injected with mRNA
encoding wild-type Xhes6 or MEKS→E alone or in combination, is shown. Data are from a typical experiment performed in triplicate. (F–J) 500 pg of Xhes6 or
ΔWRPW mRNA, alone or in combination with MEK1S→E mRNAwas injected into the marginal zone of one blastomere at 2-cell stage, along with β-galactosidase
mRNA (red staining). Gastrula stage embryos were analysed for expression of Xhes6 (E) or XmyoD (G–K) by whole-mount in situ hybridisation. The side view of the
area within the yellow box is shown on the right of each panel.
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Fig. 4. Xhes6 requires FGF signaling to induce XmyoD. (A–E) 500 pg of Xhes6 mRNAwas injected alone or in combination with 125 pg of XFD mRNA into either
the marginal zone of one blastomere at 2-cell stage, along with β-galactosidase mRNA (red staining). Gastrula stage embryos were analysed for XmyoD expression
(A–D). (E) Summary of in situ hybridisation results.
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MAPK activity, U0126, blocks the ability of Xhes6 to induce
mesodermal genes, such as Xbra and Xwnt8, indicating that
MAPK signaling is essential for mesoderm induction by Xhes6
(Supplementary Figs. 1A, B) (Favata et al., 1998). In contrast,
the activin receptor ALK5 inhibitor, SB431542, only partially
inhibits Xhes6 activity (Supplementary Figs. 1A, B) (Inman et
al., 2002). This demonstrates that Xhes6-mediated induction of
mesodermal genes is fully dependent on FGF/MAPK signaling,
but only partially dependent on signaling downstream of
activin.
Xhes6 acts on downstream targets of the FGF/MAPK and
activin/Smad2 pathways to induce XmyoD
The results above indicate that Xhes6 induces XmyoD by
interaction with the FGF/MAPK and/or activin signaling
pathways or their downstream targets. To distinguish between
these possibilities, we examined the effects of Xhes6 on the
levels of the phosphoprotein targets of both pathways
(Supplementary Fig. 2). We examined levels of the phosphory-
lated form of the MAPK target ERK in animal caps treated with
FGF, but found no differences in the level of phospho-ERK in
the presence of either wild-type or mutant Xhes6 (Supplemen-
tary Fig. 2A). This indicates that Xhes6 interacts with targets
further downstream in the FGF/MAPK pathway to enhance
mesodermal gene expression. Similar results were found when
the effect of Xhes6 expression on levels of phospho-Smad2
following activin treatment was examined. In early Xenopus
embryos, Smad2 is solely responsible for activin signal
transduction (Howell et al., 2001), yet there was no significant
difference in phospho-Smad2 levels in the presence of Xhes6
(Supplementary Fig. 2B). Thus Xhes6 either interacts with
targets of the FGF and activin pathways, downstream of MAPK
and Smad2, respectively, or acts in parallel with these pathways
to promote mesoderm formation and induction of XmyoD
expression in animal caps.Xhes6 is required for induction of XmyoD
Taken together, our results support a role for Xhes6 in
regulating XmyoD expression by acting downstream of or in
parallel with the FGF/MAPK and activin signaling pathway(s).
This raises the question as to whether Xhes6 is required for
XmyoD expression in early gastrula embryos. To address this,
we used Xhes6 antisense morpholino oligonucleotides (MOs) to
block translation of Xhes6 protein.
To design the MO, the 5′ sequence of Xhes6 mRNA was
determined by 5′ RACE PCR; the published Xhes6 clone was
found to be truncated by 92 bp at its 5′ end. The full-length
cDNA encodes an in-frame initiation codon 72 bp 5′ of the
initiation codon indicated in the clone described previously (Fig.
5A; Koyano-Nakagawa et al., 2000). The additional residues
contained no conserved motifs and no functional differences
were detected between full-length Xhes6 and the clone described
originally (Fig. 5A and data not shown). Of the two potential
initiation codons, the first lacked a Kozak sequence whilst the
second codon in the same frame is in the optimal context for
initiation of transcription. It is possible that ribosomes may
bypass the first AUG and initiate translation at the 2nd AUG, to
generate two forms of the protein (Kozak, 1987).
We therefore designed two Xhes6 MO, MO-1 and MO-2,
directed to the first and second in-frame initiation codons of
Xhes6, respectively (Fig. 5A). To test for their ability to block
translation embryos were injected with Xhes6-HA mRNA
either alone or together with MO-1, MO-2 or a control MO.
Western blotting of extracts from stage 11 embryos revealed that
Xhes6-HA protein was undetectable in the presence of MO-1
(Fig. 5B), whilst standard or 5-bp mismatched control MO had
no effect on Xhes6-HA levels (Fig. 5B and data not shown).
MO-2 inhibited Xhes6-HA translation by approximately 50%,
whilst levels of Xhes6-HA were unaltered by a 5-bp mis-
matched MO-2 control (5-mis MO-2, data not shown).
We then investigated the effects of injection of Xhes6 MOs
on Xbra and XmyoD expression in gastrula embryos. Control
68 K. Murai et al. / Developmental Biology 312 (2007) 61–76MO, MO-1 or MO-2 was injected into one blastomere of 8-cell
stage embryos to target the marginal zone of mesoderm. These
embryos were then analysed for XmyoD induction by in situ
hybridisation at gastrula stage (Figs. 5H–L). Embryos injectedwith a standard control MO (STD-CTL) or 5-mis MO-2 retained
normal XmyoD expression (Figs. 5I, J; Table 2). However,
XmyoD expression was significantly reduced in the region of
the lateral and ventral marginal zone targeted by MO-1 or
Table 2
Effect of antisense Xhes6 MO on XmyoD expression at gastrula stage and rescue
of the Xhes6 MO phenotype
MO/RNA Decreased (%) Normal (%) Total (n)
Uninjected 74
STD 1 (2.5) 39 (98) 40
5-mis MO-2 2 (7.1) 26 (93) 28
MO-1 55 (82) 12 (18) 67
MO-2 29 (94) 2 (6) 31
Rescue
MO-1+WT 9 a (43) 12 (57) 21
MO-1+DBM 9a (39) 14 (61) 23
MO-1+ΔWRPW 14 (78) 4 (22) 18
a Embryos showed decreased XmyoD expression at Xhes6 MO1 injected site,
but the less extent.
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respectively (Figs. 5K, L; Table 2). The control MO had no
effects on Xbra expression (Figs. 5D, E) and in contrast to their
effects on XmyoD expression, neither MO-1 nor MO-2 altered
levels of Xbra transcript (Figs. 5F, G). Similarly, neither the
control MO, nor MO-1 nor MO-2 caused a significant alteration
in the levels of levels of Xwnt8, Chordin or XSox17a, whilst a
reduction in expression of the myogenic transcription factor
Xmyf5 was seen in 30–40% of embryos (Supplementary Fig.
3 and data not shown).
To determine whether the effects seen were due to specific
depletion of endogenous Xhes6, we attempted to rescue the
MO-1 phenotype with 5′ truncated wild-type and mutant forms
of Xhes6, which lack sequence complementarity to MO-1 (see
Materials and methods; Fig. 5A). Co-injection of MO-1 with 5′
truncated Xhes6 mRNA restored a normal pattern of XmyoD
expression in the majority of embryos (Figs. 5M, N and Table
2). To determine which aspect of Xhes6 function is required for
mesoderm induction, we attempted rescue with mutant forms of
Xhes6. Xhes6 DBM co-injected with MO-1 rescued XmyoD
expression in most embryos (Fig. 5O, Table 2). In contrast, the
ΔWRPW mutant demonstrated minimal rescuing activity; only
22% of embryos co-injected with ΔWRPW mRNA and MO-1
showed normal XmyoD expression, a similar proportion to that
seen when MO-1 was injected alone (Figs. 5Q, R; Table 2).
Thus Xhes6 is required for the expression of XmyoD, but not for
the expression of Xbra, in gastrula stage embryos. These
observations suggest that Xhes6 regulates the specification of
mesoderm but not the initiation of mesoderm induction.Fig. 5. Antisense morpholino oligos against Xhes6 block XmyoD expression in late
reported 5′ end of the transcript is indicated by the triangle; an additional 81 base pairs
(bold). The sequences targeted by Xhes6 antisense morpholino oligonucleotides, MO
(MO) validation. Both cells of 2-cell stage embryos were injected with 1 ng Xhes6-HA
MO-1 in the amounts shown. Embryos were lysed at stage 11 and analyzed for Xhes6
membrane was also blotted with anti-α-tubulin antibody as a loading control. (C–L) P
uninjected or MO-injected embryos. 40 ng of each indicated MO together with 0.25 n
blastomere of embryos at the 8-cell stage. Embryos were analyzed by whole-mount i
gastrula stage; red colour indicates presence of β-galactosidase detected by salmon-ga
(D, I); 5-mis MO-2, a 5 base pair mismatched control version of Xhes6 MO-2 (E, J); X
shown in panel A. (M–R) Rescue of Xhes6 MO phenotype. 40 ng of MO-1 was inje
together with β-galactosidase mRNA into the marginal zone of one blastomere of 8-c
hybridisations for XmyoD; red colour indicates presence of β-galactosidase, the yellInterestingly Xhes6 does not need to bind to DNA for this
activity but does require protein–protein interactions mediated
by the WRPW domain.
Xhes6 is required for XmyoD induction by eFGF
Having established that Xhes6 is required for XmyoD
induction, we next addressed whether Xhes6 is essential for
XmyoD induction by FGF. mRNA encoding eFGF was injected
into the animal pole of 2-cell stage blastomeres, either alone or
in combination with control MO or MO-1 targeting Xhes6
translation. Expression of Xbra and XmyoD was then analysed
at mid gastrula stage (Fig. 6). eFGF alone or in combination
with the control MO expanded the region of both Xbra and
XmyoD expression (Figs. 6B, C and F, G). However, the
Xhes6 MO blocked the effect of eFGF on ectopic XmyoD
expression whilst having no effect on Xbra expression (Figs.
6D, H) consistent with its effect on endogenous Xbra
expression (Figs. 5F, G). Thus eFGF-mediated induction of
XmyoD requires Xhes6.
Xhes6 is co-expressed with Xgrg2 and Xgrg4 in lateral and
ventral mesoderm
One striking finding from this study is that the WRPW
domain of Xhes6 is very important for Xhes6-mediated
mesoderm induction. This WRPW domain has shown to bind
to members of the Groucho family of transcriptional repressors
(Fisher et al., 1996; Gratton et al., 2003). This led us to
investigate whether interactions between Xhes6 and Groucho
proteins could explain the ability of Xhes6 to enhance induction
of XmyoD.
We began by examining the expression pattern of Xenopus
Groucho homologues, Xgrg2 and Xgrg4, which have the
highest degree of sequence conservation with the well-
characterized Drosophila Groucho protein (Hasson et al.,
2005). Xgrg2 mRNA was detected throughout the gastrula
stage embryo except in endoderm, its expression overlapping
with the domain of Xhes6 expression in the lateral and ventral
mesoderm (Figs. 7A, B). Xgrg4 is also detectable at low levels
in lateral and ventral mesoderm, as reported previously (Fig.
7C; Molenaar et al., 2000). Xhes6 is thus co-expressed with
both Xgrg2 and Xgrg4 in the lateral and ventral mesoderm of
gastrula stage embryos.ral and ventral mesoderm. (A) The 5′ region of Xhes6 cDNA. The previously
of sequence were identified by 5′RACE PCR. Two initiation codons are present
-1 and MO-2 are underlined in red. (B) Antisense morpholino oligonucleotide
mRNA together with either no MO (−), a standard control MO (CTL) or Xhes6
-HA protein expression by western blotting with an anti-HA antibody. The same
henotype of Xhes6 MO. Whole-mount in situ hybridisations showing XmyoD in
g of β-galactosidase mRNA, as a tracer, were injected into marginal zone of one
n situ hybridisation to detect mRNA encoding Xbra (C–G) or XmyoD (H–L) at
l, the yellow arrow indicates the targeted region. STD-CTL, standard control MO
hes6 MO-1 (F, K) and Xhes6 MO-2 (G, L) are directed against Xhes6mRNA as
cted with mRNA encoding Xhes6 (M, N), DBM (O, P) or MT-ΔWRPW (Q, R)
ell stage embryos. Gastrula stage embryos were analysed by whole-mount in situ
ow box outlines the targeted regions shown enlarged in panels I, K and M.
Fig. 6. Xhes6 morpholino inhibits ectopic XmyoD expression by FGF-signaling. 1 pg of eFGF was injected alone or with 40 ng of STD CTL or Xhes6 in the animal
pole of a blastomere at 2-cell stage, along with β-galactosidase mRNA (red staining) and analyzed at gastrula stage for Xbra (A–D) and XmyoD (E–H) expression by
whole-mount in situ hybridisation. The side view of the area within the yellow box is shown on the right of each panel. (I) Summary of in situ hybridisation results.
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Next, we examined the effects of overexpression of un-
tagged or epitope-tagged Xgrg2 and Xgrg4 on mesoderm in-
duction and specification. Injection of mRNA encoding-tagged
or untagged forms of either protein was found to inhibit XmyoD
expression in about one third of gastrula embryos, consistent
with Groucho inhibiting XmyoD induction (Figs. 7D, F, and
data not shown). We used tagged forms of Groucho in further
experiments. One explanation for the modest penetrance of the
Xgrg phenotype is that the function of Groucho proteins is
known to be inhibited following phosphorylation by activated
ERK which is a downstream effector of MAPK (Hasson et al.,
2005). The MAPK pathway is activated in the lateral and
ventral mesoderm, and therefore may attenuate the function of
Xgrg proteins in this region (Christen and Slack, 1999). To test
this possibility, we constructed mutant forms of Xgrg2 and
Xgrg4 in which the serine residues at each of the consensus
ERK target sites were converted to either alanine or aspartate,
creating constitutively active, non-phosphorylatable mutants(Xgrg2AAA and Xgrg4AA) and pseudophosphorylated
mutants (Xgrg2DDD and Xgrg4DD), respectively. We then
examined the effects of injection of mRNA encoding the
mutants on XmyoD expression at gastrula stage. Xgrg2AAA,
and Xgrg4AA, both resistant to phosphorylation by ERK,
inhibited XmyoD expression in the majority of embryos, whilst
the pseudo-phosphorylated mutants had minimal activity (Figs.
7E, G; Table 3). These observations suggest that the low pene-
trance of the wild-type Xgrg2 and Xgrg4 phenotypes may be due
to MAPK activity inhibiting Groucho function in the lateral and
ventral mesoderm.
Inhibition of XmyoD expression by Xgrg proteins is
consistent with their acting as negative regulators of XmyoD
induction by pathways including FGF/MAPK (Fisher et al.,
2002). To investigate if this is the case, we examined the effect
of the constitutively active Xgrg mutants on induction of
XmyoD by the constitutively active MEK1S→E mutant (Fig.
7H). We found that both Xgrg2 and Xgrg4 mutants decreased,
but did not abolish the ability of MEK1S→E to induce XmyoD
(Figs. 7I, J). The fact that inhibition of MEK1S→E is only
Fig. 7. Xgrg2 and Xgrg4 inhibit XmyoD induction by MAPK signaling. Gastrula stage embryos were analysed for Xhes6 (A), Xgrg2 (B), Xgrg4 (C) and XmyoD (D–J)
expression by whole-mount in situ hybridisation. (A–C) Uninjected embryos. (D–G) 1 ng flag-tagged Xgrg2, Xgrg4 or non-phosphorylatable mutant (Xgrg2AAA or
Xgrg4AA) was injected with β-galactosidase mRNA (red staining) into marginal zone of a blastomere at 2-cell stage. (H–J) 1 ng of active MEK1 (MEK1S→E) mRNA
was injected alone or with flag-tagged Xgrg2AAA or Xgrg4AA into a blastomere at the 2-cell stage.
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inhibits the function of the Groucho mutants (Fig. 3F).
Xhes6 relieves inhibition mediated by Xgrg2 and Xgrg4
The results described above offer a mechanism for Xhes6 to
regulate mesodermal patterning. Xhes6 might bind Xgrg2 and
Xgrg4 proteins to relieve their repression of XmyoD within the
region of Xhes6 expression. If this is the case, we postulated that
overexpression of wild-type Xhes6, but not the ΔWRPW
mutant, should overcome the ability of the activated Xgrg to
inhibit XmyoD expression. mRNAs encoding constitutively
active Xgrg mutants were injected into 2-cell stage embryos
together with wild-type Xhes6 or ΔWRPW mutant and XmyoD
expression was analysed (Figs. 8A–H). While constitutively
active Xgrg2 an Xgrg4 both inhibited XmyoD expression (Figs.
8B, F; Table 3), XmyoD expression was restored with co-
injected wild-type Xhes6 (Figs. 8C, G; Table 3) but not with the
ΔWRPW mutant (Fig. 8D, H; Table 3). Consistent with these
observations, co-immunoprecipitation experiments using gas-
trula stage embryos expressing epitope-taggedXgrg2 and Xhes6or its mutant demonstrated that Xhes6 can physically interact
with Xgrg2 (Fig. 8I). The DBM mutant also bound to Xgrg2
whilst the ΔWRPW mutant did not (Fig. 8I), indicating that the
interaction is mediated via WRPW motif. Interestingly Xhes6
can interact with all forms of Xgrg2, irrespective of phosphor-
ylation status. Similar results were obtained with Xgrg4 (data not
shown). Overexpression experiments need to be interpreted with
caution as the high levels of the overexpressed protein may lead
to non-physiological interactions. However, our results are
consistent with Xhes6 relieving the repression of XmyoD
induction resulting from Groucho overexpression by directly
binding Groucho proteins. As Xhes6 is confined to the lateral
and ventral mesoderm, this suggests that Xhes6 may function in
a compartment-specific manner by regulating of endogenous
Groucho proteins.
Hes6 is required for normal myogenesis in later development
The observation that hes6 is required for XmyoD induction
in gastrulation raises the issue of whether there is a requirement
for hes6 for XmyoD expression at later stages of development.
Table 3










Uninjected 0 1 (0.6) 192 (99) 193
XGrg2 0 47 (34) 90 (66) 137
XGrg2AAA 0 88 (75) 30 (25) 118
XGrg2DDD 0 4 (6.3) 59 (94) 63
XGrg4 0 56 (34) 107 (66) 163
XGrg4AA 0 42 (56) 33 (44) 75
XGrg4DD 0 0 65 (100) 65
Xhes6 129 (82) 0 28 (18) 157
Xhes6+XGrg2AAA 33 (42) 10 (13) 35 (45) 78
Xhes6+XGrg4AA 27 (47) 0 30 (53) 57
ΔWRPW 0 0 63 (100) 63
ΔWRPW+XGrg2AAA 0 32 (71) 13 (29) 45
ΔWRPW+XGrg4AA 0 23 (45) 28 (55) 51
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against Xhes6 on expression of XmyoD at neurula stage. MO-1
significantly reduced XmyoD induction, particularly in the
posterior region of the embryos, whilst MO-2 produced a more
modest effect (Supplementary Figs. 5A–E).
Finally, our observations raise the question of whether loss of
Xhes6 affects myogenesis at later stages of development. We
therefore examined the phenotype of embryos injected with
Xhes6 MO at tail bud stage. Morphant embryos exhibited a
subtle phenotype of shortening of the tail bud, with some
embryos exhibitingmarked twisting of the body (Supplementary
Figs. 6A–D). To assess whether loss of Xhes6 had an effect on
myogenic differentiation we examined the expression of myosin
heavy chain (mhc), a marker of terminal muscle differentiation,
at tail bud stage in embryos injected with Xhes6 MO
(Supplementary Figs. 6E–H). We found that both Xhes6 MO
produced a moderate reduction in the levelmhc expression and a
loss of the normal somite pattern (Supplementary Figs. 6I–J).
We conclude that Xhes6 is required not only for normal
induction of XmyoD at gastrula and neurula stages, but also
for normal muscle differentiation at later stages of development.
Discussion
Xhes6 co-expressed with XmyoD in early gastrula embryos,
leading us to investigatewhetherXhes6 plays a role inmesoderm
induction and/or specification. We found that overexpression of
Xhes6 alone results in modest induction of mesodermal markers
in animal caps. Xhes6 cooperates with mesoderm-inducing
pathways, acting downstream of the FGF target ERK and the
activin target Smad2 to induce markers of early mesoderm and
lateral and ventral specific mesoderm as well as XmyoD in
animal caps. In vivo, however, the effects of loss ofXhes6 protein
are restricted to mesoderm specification. Xhes6 is required for
FGF-mediated induction ofXmyoD, but not for induction of pan-
mesodermal marker, Xbra. Significantly, all of these functions of
Xhes6 require the Groucho binding WRPW domain of the
protein. Xenopus Groucho, Xgrg2 and Xgrg4 are expressed in
mesoderm and elsewhere. Strikingly, overexpression ofGroucho
proteins inhibits XmyoD expression, an inhibition that isalleviated by Xhes6 in a WRPW domain-dependent manner.
Thus, Xhes6 acts downstream of and/or in parallel to mesoderm-
inducing pathways and to regulate mesoderm specification by
relieving Groucho-mediated inhibition of XmyoD.
Whilst Xhes6 requires the ability to bind Groucho to mediate
its effects on XmyoD expression, DNA-binding is not required.
This is consistent with previous studies and indicates that Xhes6
either acts by binding to a DNA-bound protein to regulate
transcription, in a Groucho-dependent manner, or acts indepen-
dent of DNA binding, by binding Groucho to prevent its
recruitment by other transcription factors (Cossins et al., 2002;
Jhas et al., 2006; Koyano-Nakagawa et al., 2000). An important
issue is whether the results seen in this study are confined to
Xhes6, or whether any hes family member would have similar
effects. Strikingly, overexpression of Xhairy1 or Xhairy2 results
in decreased XmyoD expression in gastrula stage embryos, the
direct opposite of the phenotype produced by Xhes6 (Cui, 2005;
Umbhauer et al., 2001). Furthermore, the inhibition of XmyoD
expression does not require the Xhairy WRPW motif, suggest-
ing that Xgrg proteins are not involved. These observations
suggest that Xhes6 does indeed have a specific function, distinct
from other hes proteins, in regulating mesodermal specification.
Here we have shown that the Xgrg protein family inhibits the
induction of XmyoD. Although phosphorylation of Xgrg
proteins by ERK attenuates their repressor activity (Table 3;
Hasson et al., 2005), ERK activity alone is insufficient to relieve
Xgrg-mediated repression of MAPK inducible genes during
mesoderm specification. Xhes6 has no effect on phospho ERK
levels (Supplementary Fig. 2A), so does not alter Groucho
phosphorylation. We postulate that Xhes6 is required to
augment the effects of ERK phosphorylation, binding Xgrg
proteins directly to relieve Groucho-mediated inhibition of FGF
targets such as XmyoD (Supplementary Fig. 4).
In addition to being required for XmyoD induction at
gastrulation, Xhes6 is also required for XmyoD expression in
the posterior region of neurula stage embryos (Supplementary
Fig. 5). This is again consistent with Xhes6 acting via FGF
signaling, as pharmacological inhibition of the FGF receptor
has been shown to inhibit XmyoD induction in posterior, but not
anterior explants of stage 15–19 embryos (Standley et al.,
2002). The disruption of the tail bud seen in Xhes6 morphant
embryos is consistent with the high expression of Xhes6 in the
tail bud and resembles the posterior phenotype produced by
FGF8 MO at tail bud stage (Supplementary Fig. 6; Cossins et
al., 2002; Fletcher et al., 2006).
Finally, the lowering Xhes6 levels results in significant
disruption of myogenesis, evidenced by the reduction of mhc
expression in tail bud stage embryos (Supplementary Fig. 6). It
remains to be determined whether this is due to the effects of
Xhes6 on XmyoD expression, but this observation does indicate
Xhes6 has a key role in myogenic differentiation.
Materials and methods
Isolation of full-length Xhes6 cDNA by 5′RACE
5′RACE PCR of cDNA from stage 11 Xenopus embryos was used to
determine the sequence of the 5′UTR and translation initiation codon of Xhes6
Fig. 8. Xhes6 interact with Xgrg2 and Xgrg4 and relieves inhibition. 1 ng flag-tagged Xgrg2 or Xgrg4 mRNA were injected alone or with 500 pg MT-Xhes6 or
ΔWRPW to together with β-galactosidase mRNA (red staining) into marginal zone of a blastomere at 2-cell stage. (A–H) In situ hybridisation for XmyoD was
performed on gastrula stage embryos. The side views of embryos were shown on the right (A–H). The arrow indicated the injected region. (I) Immunoprecipitations
were carried out using whole lysate from gastrula embryos and the immunocomplex was analysed by western blotting.




RACE clones contained an additional 61–92 bp 5′ sequence compared with
the original Xhes6 cDNA (Koyano-Nakagawa et al., 2000). The full-lengthsequence of Xhes6 is identical to that of the Xenopus image clone accession
number BC130161.
Plasmid, mRNA and in situ probes
N-Terminally myc-tagged Xhe6, DBM and ΔWRPW constructs were
constructed by subcloning of an EcoRI fragment from Xhes6, DBM or
ΔWRPW into MT (Koyano-Nakagawa et al., 2000). For construction of
74 K. Murai et al. / Developmental Biology 312 (2007) 61–76Xhes6HA, first Xhes6 cDNA excluding stop codon was amplified by PCR and
subcloned into pCS2+. Following Xho I digestion, a synthesized fragment
encoding an HA epitope was inserted. cDNAs encoding Xgrg2 and Xgrg4 were
amplified by PCR from MGC clones (Geneservice) and inserted into pCS2+.
Ala or Asp substitutions at S266/S294/S559 of Xgrg2 and S266/S293 of Xgrg4
were introduced by sequential site-directed mutagenesis. Following Cla I–Xho I
digestion, a synthesized fragment encoding a flag epitope was inserted into all
Xgrg2 and Xgrg4 constructs.
Plasmids used were pXFD/Xss, encoding a dominant negative FGF receptor
(Amaya et al., 1991), MAPKK1S217E/S221E, encoding an activated mutant of
MEK1 (MEKS→E; Cowley et al., 1994), eFGF, (Lombardo and Slack, 1997),
Xnr2 (Jones et al., 1995) and cytoplasmic β-galactosidase as a tracer. Capped
mRNAwas synthesized in vitro from linearised plasmids using the SP6Message
Machine kit (Ambion).
Antisense RNA in situ hybridisation probes were generated as described
(Hopwood et al., 1989; Smith et al., 1991).
Xenopus embryos and injection of mRNA and morpholinos
Xenopus embryos obtained by hormone-induced laying were in vitro
fertilized, dejellied in 2% cysteine pH 8.0, and washed in 0.1× MBS. Capped
mRNAs were injected into embryos in 0.2× MBS supplemented with 4% Ficoll
and 25 μg/ml gentamicin (Gibco). Amounts of injected mRNA and stages of
embryos are as described in the figure legends.
Morpholinos against Xhes6 were:
Xhes6 MO-1, 5′TCTGCCTGCGCTCCATGTGATTGTT;
Standard control MO (STD-CTL), 5′CCT CTT ACC TCA GTTACA ATT
TAT A
Xhes6 MO-2, 5′CATGGTAGATGAATAAGGACACACG;
5-mis Xhes6 MO-2, 5′CATcGTAcATcAATAAcGACAgACG (Gene Tools
LLC).
Animal cap assays
Animal caps were dissected from stage 9 embryos and explants were cultured
in 0.7×MBS containing 0.1% BSA and 25 μg/ml gentamicin (Gibco). For growth
factor stimulation, caps were incubated with 20 ng/ml of human FGF2 (bFGF),
FGF4 or 1–5 ng/ml activin (R&D Systems). To inhibit the activin andMAP kinase
signaling pathways, 20 μM SB431542 (Tocris) or 40 μM U0126 (Calbiochem)
were added to the culture (Favata et al., 1998; Inman et al., 2002). To confirm the
specificity and efficiency of the inhibitors, animal caps were dissected at stage 9
and treated with FGF or activin in the presence or absence of the MEK inhibitor,
U0126 (U0) or SB431542 (SB), or an inhibitor of the activin receptor, ALK5.
Activation of each signaling pathway was determined by Western blotting using
antibodies against total and phosphorylated forms of ERK or Smad2.
Real-time PCR analysis
Total RNAwas isolated from Xenopus embryos or animal caps using Qiagen
RNeasy mini kit according to the manufacture’s instructions. cDNA was
synthesized by Superscript II (Invitrogen). Quantitative PCR using SYBR Green
PCR mix (Qiagen) was performed on Corbett Research RotorGene PCRmachine.
Primer sequences are as follows:
ODC, 5′GCCATTGTGAAGACTCTCTCCATTC3′ and
5′TTCGGGTGATTCCTTGCCAC3′ (Heasman et al., 2000);
Xbra, 5′TTCTGAAGGTGAGCATGTCG3′ and
5′GTTTGACTTTGCTAAAAGAGACAGG3′ (Sun et al., 1999);
XmyoD, 5′AGCTCCAACTGCTCCGACGGCATGAA3′ and




5′TTTGTCCATAGGTTCCGCCCTG3′ (Xanthos et al., 2001);
Mix.2, 5′TGCAAGCCATCATTATTCTAGC3′ and
5′AGGAACCTCTGCCTCGAGACAT3′ (Xanthos et al., 2001);Mixer, 5′CACCAGCCCAGCACTTAACC3′ and
5′CAATGTCACATCAACTGAAG3′ (Henry and Melton, 1998);
Xsox17α, 5′GCAAGATGCTTGGCAAGTCG3′ and
5′GCTGAAGTTCTCTAGACACA3′ (Xanthos et al., 2001);
Xwnt8, 5′CTGATGCCTTCAGTTCTGTGG3′ and
5′CTACCTGTTTGCATTGCTCGC3′ (Ding et al., 1998).
Whole-mount in situ hybridisation
Xenopus embryos were fixed for 1 h in MEMFA and stained for β-
galactosidase (250 pg mRNA injected embryo) using Salmon Gal (Research
Organics). Whole-mount in situ hybridisation was carried out as described
(Shimamura et al., 1994) with Dig (Roche)-labelled antisense RNA probe.
Western blotting and immunoprecipitation
Total protein extracts were separated by SDS–PAGE and transferred to
nitrocellulose (immobilon-P; Millipore) by standard methods. Primary anti-
bodies are as follows: anti-c-myc (9E10) and anti-Smad2/3 (Santa Cruz
Biotechnology, Inc.); anti-FLAG M2 HRP, anti-α-tubulin (Sigma-Aldrich) and
anti-phospho-Smad2, anti-p44/p42 MAPK, anti-phospho-p44/p42 MAPK
(Ser465/467), anti-HA and anti-Myc tag polyclonal (Cell Signalling Technol-
ogy). For immunoprecipitation, Xenopus embryos were lysed at gastrula stage
and whole lysate incubated with either anti-FLAG M2 affinity gel or Ezview
Red anti-c-myc affinity gel (Sigma-Aldrich). Immunocomplex formation was
analyzed by western blotting.Acknowledgments
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